Company news
Puma Biotechnology Inc (NASDAQ:PBYI) news
Every Puma Biotechnology Inc press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results
July 23, 2026
Puma Biotechnology Reports First Quarter 2026 Financial Results
May 7, 2026
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results
April 23, 2026
Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results
February 26, 2026
Puma Biotechnology to Present at TD Cowen’s 46th Annual Health Care Conference
February 23, 2026
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results
February 12, 2026
Rigel Appoints Michael P. Miller to the Board of Directors
February 3, 2026
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
January 7, 2026
Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI)
December 22, 2025
Puma Biotechnology Reports Third Quarter 2025 Financial Results
November 6, 2025
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
October 23, 2025
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635c4
October 3, 2025
Puma Biotechnology to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
Puma Biotechnology Reports Second Quarter Financial Results
August 7, 2025
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial Results
July 24, 2025
Puma Biotechnology Reports First Quarter Financial Results
May 8, 2025
Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients
April 30, 2025
Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025
April 28, 2025
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results
April 24, 2025
Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025
March 26, 2025
Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference
March 5, 2025
Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results
February 27, 2025
Puma Biotechnology to Present at TD Cowen’s 45th Annual Health Care Conference
February 26, 2025
Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation
December 23, 2024
Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metast...
November 20, 2024
Puma Biotechnology Reports Third Quarter 2024 Financial Results
November 7, 2024
Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer
June 3, 2024
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer ...
June 2, 2024
Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting
May 23, 2024
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Brea...
March 20, 2024
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
February 29, 2024
Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer
February 13, 2024
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast C...
December 11, 2023
Puma Biotechnology Reports Third Quarter 2023 Financial Results
November 2, 2023
Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Ne...
October 14, 2023
Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer
August 8, 2023
Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alon...
June 4, 2023
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology
March 14, 2023
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
March 2, 2023
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results
February 16, 2023
Puma Biotechnology Releases Updated Corporate Presentation
January 9, 2023
Puma Biotechnology Reports Third Quarter 2022 Financial Results
November 3, 2022
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 ...
October 27, 2022
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investiga...
September 20, 2022
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cer...
September 11, 2022
Puma Biotechnology Reports Second Quarter 2022 Financial Results
August 4, 2022
Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2022 ASCO Annual Meeting
May 26, 2022
Puma Biotechnology Reports First Quarter 2022 Financial Results
May 5, 2022
Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
April 21, 2022
Puma Biotechnology Announces $10 Million Private Placement
March 10, 2022